Patent ID: 8637005

Claim:
A method of treating or repairing a vascular injury caused by vascular insufficiency in a subject in need thereof, comprising: parenterally administering to the subject through a catheter a sterile pharmaceutical composition comprising: (a) a therapeutic amount of a sterile chemotactic hematopoietic stem cell product, wherein the therapeutic amount is effective to repair a vascular injury caused by vascular insufficiency, the chemotactic hematopoietic stem cell product comprising a nonexpanded isolated population of autologous mononuclear cells comprising a subpopulation of CD34+ cells, which further contains a subpopulation of potent SDF-1-mobile CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity, wherein the therapeutic amount of the chemotactic hematopoietic stem cell product comprises at least 0.5×10 6 potent SDF-1 mobile CD34+/CXCR-4+ cells that have CXCR-4 mediated chemotactic activity; and (b) a stabilizing amount of serum, wherein the stabilizing amount of serum, which ranges from about 0.1% to about 70% (v/v) of the composition, is effective to retain the CXCR-4 mediated chemotactic activity and hematopoietic colony forming activity of the subpopulation of SDF-1 mobile CD34+/CXCR-4+ cells from completion of acquisition of the nonexpanded population of autologous mononuclear cells from the subject to infusion of the chemotactic hematopoietic stem cell product into the subject, wherein the pharmaceutical composition is further characterized as having the following properties for at least 24 hours following acquisition of the chemotactic hematopoietic stem cell product, when tested in vitro after passage through the catheter: (i) the subpopulation of CD34+ cells constitutes from about 1% to about 95% of the isolated nonexpanded population of autologous mononuclear cells, (ii) the subpopulation of CD34+ cells further contains a subpopulation of potent SDF-1 mobile CD34+/CXCR-4+ cells that have CXCR-4-mediated chemotactic activity; (iii) the subpopulation of CD34+ cells comprises from about 1% to about 95% viable CD34+ cells; and (iv) the subpopulation of CD34+ cells is able to form hematopoietic colonies in vitro.